Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.

[1]  K. Weber,et al.  A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  G. Hortobagyi,et al.  Current Landscape of Immunotherapy in Breast Cancer: A Review. , 2019, JAMA oncology.

[3]  A. Schneeweiss,et al.  Abstract PD2-07: mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC)– Results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial , 2019, Poster Discussion Abstracts.

[4]  T. Chan,et al.  The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy , 2019, Nature Reviews Cancer.

[5]  C. Brennan,et al.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.

[6]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[7]  J. Lunceford,et al.  Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy , 2018, Science.

[8]  Guangxu Jin,et al.  Tumor mutational burden is a determinant of immune-mediated survival in breast cancer , 2018, Oncoimmunology.

[9]  P. Gibbs,et al.  Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series , 2018, The lancet. Gastroenterology & hepatology.

[10]  L. Pusztai,et al.  Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer , 2017, JAMA oncology.

[11]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[12]  L. Pusztai,et al.  Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer. , 2017, Cancer research.

[13]  Levi Garraway,et al.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.

[14]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[15]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[16]  Carsten Denkert,et al.  Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[19]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[20]  Julian Gehring,et al.  SomaticSignatures: inferring mutational signatures from single-nucleotide variants , 2014, bioRxiv.

[21]  Zoltan Szallasi,et al.  Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations , 2013, PloS one.

[22]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[23]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[24]  Lajos Pusztai,et al.  A clinically relevant gene signature in triple negative and basal-like breast cancer , 2010, Breast Cancer Research.

[25]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. A. Morales,et al.  Multiplexed screening assay for mRNA combining nuclease protection with luminescent array detection. , 2002, Assay and drug development technologies.

[27]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. , 2001, Annals of internal medicine.

[28]  P. Fasching,et al.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. , 2018, The Lancet. Oncology.

[29]  M. Hallett,et al.  Absolute assignment of breast cancer intrinsic molecular subtype. , 2015, Journal of the National Cancer Institute.